<DOC>
	<DOCNO>NCT01898338</DOCNO>
	<brief_summary>To demonstrate combination daptomycin fosfomycin superior daptomycin alone treatment methicillin resistant Staphylococcus aureus ( MRSA ) bacteremia .</brief_summary>
	<brief_title>Efficacy Daptomycin Plus Fosfomycin Versus Daptomycin Treatment MRSA Bacteremia</brief_title>
	<detailed_description>The mortality associate MRSA bacteremia remain high 30 % episode despite availability new antibiotic . Objective : To demonstrate combination daptomycin fosfomycin superior daptomycin alone treatment methicillin resistant Staphylococcus aureus ( MRSA ) bacteremia . Design : Randomized , open-label multicenter study . Intervention : Patients MRSA bacteremia randomize ( 1:1 ) Group 1 : daptomycin 10mg/Kg/24h intravenous ( iv ) Group 2 : daptomycin 10 mg/kg/24 iv plus fosfomycin 2g/6h iv . Duration therapy 10-14 day uncomplicated bacteremia 42 day complicate bacteremia . Follow : There clinical microbiological evaluation baseline , treatment week 6 end therapy ( test cure visit , TOC ) . Complicated bacteremia consider : ) persistence positive blood culture 72-96 h start antibiotic , b ) evidence spread infection ( metastatic infection ) c ) infection involve non-removable device less 4 day . Sample size : Assuming 60 % cure rate daptomycin 20 % difference cure rate group , estimate 103 patient need group ( α:0.05 , ß : 0.2 ) . Main endpoint : clinical microbiological response TOC visit . Treatment success define resolution clinical sign symptom negative blood culture . Treatment failure define following situation : ) lack clinical response 72 h initiation study therapy b ) persistent bacteremia ( positive blood culture day 7 randomization ) , c ) withdrawal treatment due adverse effect reason base clinical judgment . ) relapse MRSA bacteremia TOC visit e ) death reason TOC visit . Secondary endpoint : evaluation group clinical microbiological response end therapy ( EOT visit ) ; mortality EOT TOC visit ; persistent MRSA bacteremia ; recurrence MRSA bacteremia ( positive blood culture previous one negative ) ; emergence daptomycin fosfomycin resistance severe adverse effect .</detailed_description>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>Patients least 1 positive blood culture MRSA within 72h randomization Adult patient , equal old 18 year old Signed informed consent Mandatory use contraception method fertile woman study period 6 month stop antibiotic therapy Polymicrobial bacteremia Pneumonia associate bacteremia Severe clinical status expect survival less 24 hour Allergy daptomycin fosfomycin A positive pregnancy test time inclusion Any clinical condition require additional antibiotic therapy microbiological activity MRSA Patient already include another clinical trial Prior history eosinophilic pneumonia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MRSA</keyword>
	<keyword>bacteremia</keyword>
	<keyword>therapy</keyword>
</DOC>